Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
6 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Moleculin said enrollment in Part A of its Phase 2/3 MIRACLE trial of Annamycin plus HiDAC in relapsed or refractory AML is complete. A full 90-patient Part A data readout is expected in Q1 2027, pending financing; the company described interim efficacy as encouraging.
Moleculin Biotech completed enrollment of 89 subjects in Part A of the pivotal Phase 2/3 MIRACLE trial, keeping a comprehensive Part A data readout on track for Q1 2027.Key Highlights:Original SEC Filing: Moleculin Biotech, Inc. [ MBRX ] - 8-K - Sep. 29, 2026This is an AI-powered summary. It may co…
Moleculin Biotech completed and closed enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial in R/R AML with 89 subjects, and expects a comprehensive Part A data readout in Q1 2027.Material DetailsContext by AI AnalystThis is a mid-stage operational milestone in a pivotal Phase 2/3 program, c…
HOUSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. NASDAQ:MBRX (“Moleculin” or the “Company”) today announced that it has completed and closed enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment…
Moleculin Biotech said it has closed Part A enrollment in its Phase 2/3 MIRACLE trial of Annamycin plus cytarabine for relapsed or refractory AML; Part A enrolled 89 patients and a comprehensive data readout is planned for Q1 2027.
Moleculin Biotech (MBRX) completed enrollment in Part A of its Phase 2/3 relapsed/refractory AML MIRACLE trial, keeping the program on track for a Q1 2027 data readout.